The Intermittent Claudication drugs in development market research report provides comprehensive information on the therapeutics under development for Intermittent Claudication, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. GlobalData’s report assesses key aspects of the companies and drugs in development for Intermittent Claudication. Buy the report here.

The report also covers the descriptive pharmacological action of the therapeutics and the latest news and press releases. Additionally, the report provides an overview of the key players involved in therapeutic development for Intermittent Claudication and features dormant and discontinued products.

GlobalData tracks five drugs in development for Intermittent Claudication by five companies/universities/institutes. The top development phase for Intermittent Claudication is phase ii with four drugs in that stage. The Intermittent Claudication pipeline has five drugs in development by companies and 0 by universities/ institutes. Some of the companies in the Intermittent Claudication pipeline products market are: Helixmith, Pluri and ID Pharma.

The key targets in the Intermittent Claudication pipeline products market include Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor or Heparin Binding Growth Factor 2 or FGF2), Hepatocyte Growth Factor (Hepatopoietin A or Scatter Factor or HGF), and Phosphodiesterase 3 (PDE3 or EC 3.1.4.17).

The key mechanisms of action in the Intermittent Claudication pipeline product include Phosphodiesterase 3 (PDE3 or EC 3.1.4.17) Inhibitor with one drug in Phase II. The Intermittent Claudication pipeline products include three routes of administration with the top ROA being Intramuscular and three key molecule types in the Intermittent Claudication pipeline products market including Gene Therapy, and Small Molecule.

Intermittent Claudication overview

Intermittent claudication is caused by a narrowing or blockage in the main artery that takes blood to leg. Symptoms include burning or tingling sensation, decreased or absent pulse in the lower limb, pale or bluish skin, poor hair growth on the legs, and sores or wounds on the lower limb that heal slowly or poorly. Risk factors include smoking, high cholesterol, high blood pressure, obesity, diabetes, age, and family history.

For a complete picture of Intermittent Claudication’s pipeline drug market, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s pipeline drugs offers detailed profiles of pharmaceutical drugs in all stages of pre-clinical and clinical development, from discovery through to pre-registration. Coverage is limited to novel human medicinal drugs and biosimilars seeking market approval proprietary and is one of two primary repositories of pharmaceutical drug information offered by GlobalData through its Pharmaceutical Intelligence Center.